Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) recently announced promising preclinical results published in Nature Biotechnology, demonstrating significant control of acute myeloid leukemia (AML) using a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. These findings indicate that CD123-NKCE can activate NK cells effectively against AML cells while minimizing toxicity. A Phase 1/2 clinical trial is currently underway, evaluating IPH6101/SAR’579 in patients with relapsed or refractory AML. Experts express optimism about its potential superiority over existing treatments.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has expanded its collaboration with Sanofi (NASDAQ: SNY) by granting an exclusive license for its B7H3 ANKETTM program. Sanofi will be accountable for all development and commercialization activities. Innate will receive an upfront payment of €25 million and up to €1.35 billion in potential milestones, along with royalties from net sales. This partnership continues the 2016 collaboration focused on NK cell engagers, enhancing Innate's cancer treatment portfolio and Sanofi's oncology strategy.
Innate Pharma, listed on Nasdaq under the ticker IPHA, recently presented encouraging results from the TELLOMAK Phase 2 trial of lacutamab for treating Sézary syndrome, demonstrating an objective response rate (ORR) of 21.6% in the intention to treat (ITT) population. In blood samples, the ORR was 37.8%, while skin samples showed 35.1% ORR. Lacutamab maintains a favorable safety profile with low incidence of severe treatment-related adverse events. The company aims to further explore lacutamab's efficacy in other T-cell lymphomas.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has provided an update on its outstanding shares as of December 1, 2022. The company reports a total of 80,812,069 ordinary shares and 6,514 and 7,581 preferred shares from 2016 and 2017, respectively. The total number of theoretical voting rights is 80,969,909, while the exercisable voting rights are noted as 80,951,334. This disclosure aligns with French stock-market regulations and aims to keep the market informed about the company’s capital structure.
Innate Pharma announced three poster presentations at the ESMO Immuno-Oncology Annual Congress on December 8, 2022, in Geneva, Switzerland. The posters include Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, presented by AstraZeneca, and preclinical data supporting its Phase 2 development in non-small cell lung cancer. The IPH5301, a CD73-blocking antibody, will also be showcased along with the trial design.
Innate Pharma reported a cash position of €151.4 million as of September 30, 2022, ensuring a cash runway into H2 2024. The company showcased preliminary data from the Phase 2 TELLOMAK trial of lacutamab, highlighting a clinical activity with a global objective response rate (ORR) of 28.6% in mycosis fungoides. Additionally, lacutamab's ongoing Phase 2 data in Sézary syndrome is set to be presented at the ASH 2022 Annual Congress on December 10. Revenues for the first nine months of 2022 reached €44.3 million, compared to €10.3 million for the same period in 2021.
Innate Pharma announced a conference call on November 14, 2022, at 2 p.m. CET / 8 a.m. ET, to discuss third-quarter business progress. Key speakers include CEO Mondher Mahjoubi and other executives. The call will be available via webcast and telephone registration, providing access for questions. Innate Pharma, focused on oncology, utilizes therapeutic antibodies to enhance cancer treatment outcomes. It has a broad pipeline and alliances with several major biopharmaceutical companies.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) is set to present preliminary results from the TELLOMAK Phase 2 trial evaluating lacutamab for advanced Sézary syndrome at the ASH Annual Meeting, December 10-13, 2022, in New Orleans. Highlights include an oral presentation by CSO Eric Vivier on the ANKET™ platform and two poster presentations by partner Sanofi on SAR'579/IPH6101 and SAR'514/IPH6401. Lacutamab, a first-in-class anti-KIR3DL2 antibody, has received EMA PRIME designation and FDA Fast Track status for treatment in Sézary syndrome patients.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) has announced that its senior management team will participate in two upcoming investor conferences. The Stifel 2022 Healthcare Conference is scheduled for November 15-16, 2022, in New York, while the Evercore ISI HealthConX Conference will take place from November 29 to December 1, 2022, virtually. Innate Pharma focuses on oncology, developing therapeutic antibodies that utilize the immune system to enhance cancer treatment outcomes. It has a robust pipeline and strategic collaborations with major biopharmaceutical companies.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has released its 2023 financial calendar, scheduling key financial reports throughout the year. Important dates include:
- March 23, 2023: Publication of 2022 financial statements
- May 10, 2023: 1Q2023 revenue announcement
- September 14, 2023: Half-year financial statements
- November 14, 2023: 3Q2023 revenue release
All reports will be made public before market open CET. For more details about the company and its activities, visit the website.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
